Laboratorio Reig Jofre, S.a. · BME:RJF
Laboratorio Reig Jofre — Reig Jofre — FY2025 Earnings Presentation
22 slides from Laboratorio Reig Jofre's earnings presentation, Mar 10, 2026
Slide 1: 2025 Results and Future Outlook
2025 Results and Future Outlook 10th March 2026 Palacio de la Bolsa de Madrid Plaza de la Lealtad 1, Madrid
Slide 2: Disclaimer
DISCLAIMER This presentation does not contain confidential material and may include publicly available market information that has not been independently verified by Reig Jofre. This information is given in summary form and does not purport to be complete. The information contained in this presentat
Slide 3: Contents
CONTENTS 1. Reig Jofre today 2. Milestone 2025 • Business growth • Specialized industrial infrastructure • Innovation 3. Financial results 4. Strategic vision
Slide 4: Reig Jofre today: Universalizing science that matters
REIG JOFRE TODAY Universalizing science that matters 96 YEARS GLOBAL COMPANY INNOVATION AND +1,500 PEOPLE Sales in over 70 countries PORTFOLIO 48% female leadership 8 European subsidiaries Products and Brands 24 nationalities 185 business partners Advanced CDMO Services COMMITMENT INDUSTRIAL SHAREHO
Slide 5: Milestones 2025
MILESTONES 2025 Sed ut perspiciatis REIG JOFRE drives a paradigm shift in the evolution of its business to maximize profitable growth Commercial International growth expansion Commitment to Vertical integration. innovation Biotechnology EMINTECH Project Efficiency and Antibiotics productivity in pro
Slide 6: Sales by business unit
SALES BY BUSINESS UNIT SALES 2025 € 331 MILLION (2%) millions of euros Sed ut perspiciatis 41% 36% 23% PHARMACEUTICAL SPECIALITY CONSUMER TECHNOLOGIES PHT PHARMACARE SPC HEALTHCARE CHC € 137 MILLION / (10 %) € 120 MILLION / +4 % € 74 MILLION / +3 % Antibiotics €48 M Dermatology €38 M ENT RJ €13 M (3
Slide 7: Global sales
GLOBAL SALES SALES 2025 € 331 MILLION (2%) millions of euros Sed ut perspiciatis Rest of Rest of the Spain RJF Sed maintains its focus on global expansion, with sales ut perspiciatis Sed ut perspiciatis Europe world outside Spain accounting for 59% of total sales. € 137 M € 157 M € 37 M 41% 48% 11%
Slide 8: International performance
INTERNATIONALPERFORMANCE SALES 2025 € 331 MILLION (2%) Sed ut perspiciatis EUROPEAN SUBSIDIARIES LICENCE AGREEMENTS ADVANCED SERVICES (B2C) DISTRIBUTION (B2B) CDMO €199 M €74 M €58 M PHT 60% 22% 18% SPC CHC 115BUSINESS 70 BUSINESS PARTNERS PARTNERS RJ Nordics Direct sales are up 5%, driven by our ei
Slide 9: Specialised industrial infrastructure
SPECIALISED INDUSTRIAL INFRASTRUCTURE Own product | Flexible CDMO services Sed ut perspiciatis Barcelona Toledo New beta-lactam antibiotics line | New injectables/lyophilized line | operational in 2026 | +capacity, operational in 2026 | productivity | productivity, efficiency | ↓unit cost | operatio
Slide 10: Commitment to innovation for almost 100 years
COMMITMENT TO INNOVATION FOR ALMOST 100 YEARS Sed ut perspiciatis Short term Mediumterm Long term 1. In specialized industrial Higher- margin business: Vertical integration: Development New technologies and advanced advanced CDMO services and and production of therapies technology finished dosage fo
Slide 11: Vertical integration: Leanbio y Syna Therapeutics
VERTICAL INTEGRATION: LEANBIO Y SYNA THERAPEUTICS From biotechnological drug substance to finished injectable pharmaceutical product Sed ut perspiciatis 2018 2023 2024 2025 JV SYNA ACCORD HEALTHCARE INVESTMENT €6.6 M INVESTMENT €3.5 M THERAPEUTICS 1st BIOSIMILAR INCREASE IN VERTICAL LICENSE SHAREHOL
Slide 12: Vertical integration: Leanbio y Syna Therapeutics
VERTICAL INTEGRATION: LEANBIO Y SYNA THERAPEUTICS From biotechnological drug substance to finished injectable pharmaceutical product Sed ut perspiciatis 400 m2 4.000 m2 Microbial Development Mammalian GMP industrial Services : facilities facilities Bioconjugates Biotechnology (Parc Científic ) devel
Slide 13: Vertical integration: Leanbio y Syna Therapeutics
VERTICAL INTEGRATION: LEANBIO Y SYNA THERAPEUTICS From biotechnological drug substance to finished injectable pharmaceutical product Sed ut perspiciatis 2018 2023 2024 2025 2026 2027 ACCORD HEALTHCARE INVESTMENT € 6,6 M INVESTMENT € 3,5 M • COMPLETION OF CLINICAL • START OF REGULATORY JV SYNA 1st BI
Slide 14: Financial results: Profit and loss account
FINANCIAL RESULTS Profit and loss account millions of euros Sales Gross margin • Sales figures amount to €331 million, - 2% vs 2024 due to a 30% reduction in antibiotic sales. 339 331 199 196 • The associated gross margin was 59% , half a point higher than in the previous year due to a better mix of
Slide 15: EBITDA waterfall
WATERFALLEBITDA millions of euros 38,1 4,1 7,7 (4,7) 0,2 30,5 +11% (9,7) (3,8) (1,4) 2024 Organic Temporary Emintech Emintech Regulated Catalyst Syna y 2025 growth reduction project project prices operational Leanbio in antibiotic grant costs reduction excellence december '25 proudction income of Co
Slide 16: Balance sheet – Assets and investments
FINANCIAL RESULTS Balance sheet – Assets and investments millions of euros ASSETS Non-current assets OPERATIONAL INVESTMENTS € 34 M € 70 M FIXED ASSETS 2024 152 INTANGIBLE ASSETS Business combination +38 Industrial investments +25 € 129 M R&D projects Digital projects +5 +4 TANGIBLE FIXED Amortisati
Slide 17: Balance sheet – Liabilities and debts
FINANCIAL RESULTS Balance sheet – Liabilities and debts millions of euros LIABILITIES Gross financial debt Net financial debt € 112 M FINANCIAL DEBT 2024 67 FINANCIAL DEBT Business combination +28 Credit institutions +6 € 9 M Leases Other financial liabilities +0 +11 101 OTHER NON- 76 CURRENT FINANC
Slide 18: Strategic vision
STRATEGIC VISION Focus on profitable growth and operating cash generation Sed ut perspiciatis + GLOBAL 1 2 3 Business growth Recover growth in: Antibiotics and injectables through B2C direct sales sales, EBITDA (double digits) Launch of new lines 3 Business Units and and Net Profit in ‘26 vs ’25 Inc
Slide 19: Solid fundamentals and a clear strategy to capture future growth
We have solid fundamentals and a clear strategy to capture future growth. REIG JOFRE is built on strategic and critical assets, industrial capacity, cutting - edge technology, integrated biotechnology, and a defined roadmap to accelerate profitable, sustainable growth, guided by a clear purpose: Uni
Slide 20: Alternative performance measures
ALTERNATIVE PERFORMANCE MEASURES Management uses certain alternative performance measures in making financial, operating and planning decisions, as well as to evaluate the performance of the Group and its subsidiaries. Management believes that these alternative performance measures provide additiona
Slide 21: Links and additional information
LINKS AND ADDITIONAL INFORMATION FINANCIAL AND BUSSINESS INFORMATION • Results | Laboratorio Reig Jofre COMMUNICATIONS TO THE CNMV • Other relevant information | Laboratorio Reig Jofre NEWSLETTER SUBSCRIPTION CENTER • Newsletter | Laboratorio Reig Jofre LATEST NEWS • News | Laboratorio Reig Jofre •
Slide 22: C/ Gran Capitán, 10 08970 Sant Joan Despí BARCELONA, SPAIN
C/ Gran Capitán, 10 08970 Sant Joan Despí BARCELONA, SPAIN T. +34 93 480 67 10 www.reigjofre.com www.reigjofre.com reigjofre.com reigjofre.com